SecBot SecBot
PRESS-RELEASE ·Filed Mar 9, 2026

SGP

SpyGlass Pharma, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The strong 12-month safety and efficacy data de-risk the Phase 3 program and increase the probability of regulatory success. Traders should monitor upcoming data presentations and Phase 3 enrollment milestones as catalysts. The 505(b)(2) pathway could accelerate approval timeline relative to traditional NDA routes.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$27.12
T+0 close · Mar 9, 2026 · via day close
Latest settled
−32.30%
T+60 · $18.36
Vs SPY
−44.29%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 9 $27.12entry
  2. T+1 · 8mo ago −1.11%α −0.92% · $26.82
  3. T+5 · 8mo ago −0.07%α +1.28% · $27.10
  4. T+20 · 7mo ago −22.31%α −19.50% · $21.07
  5. T+60 · 6mo ago −32.30%α −44.29% · $18.36
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

SpyGlass Pharma announced positive 12-month results from its Phase 1/2 trial of the BIM-IOL System, showing sustained intraocular pressure (IOP) reduction, high rates of freedom from topical glaucoma medications (97%), and vision outcomes comparable to standard IOLs. The data support the ongoing Phase 3 trials aimed at FDA approval via a 505(b)(2) NDA pathway.

Key Facts

  • 97% of BIM-IOL patients discontinued all topical IOP-lowering therapy at 12 months
  • 34% and 42% mean IOP reduction from baseline in 78-mcg and 39-mcg dose groups, respectively, vs. 35% in control
  • 100% of patients achieved 20/32 or better vision, with mean BCDVA equivalent to 20/20
  • Adverse event rates were similar across treatment and control groups, with no serious ocular events
  • Two identical Phase 3 trials for the 78-mcg dose are now enrolling, following first patient dosing in January 2026

Financial Impact

Potential blockbuster impact if Phase 3 confirms results, addresses $2B+ U.S. glaucoma drop market with a surgically delivered, adherence-free solution

revenuevaluationdilution

Risk Factors

  • Phase 3 trials may not replicate Phase 1/2 results despite similar design
  • Regulatory hurdles in combining a drug (bimatoprost) with a device (IOL) under 505(b)(2)
  • Commercial adoption depends on reimbursement and surgeon uptake despite broad cataract surgeon accessibility claims

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3251760

Track record

9 reports on SGP

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +33.66% at T+20 after the Oct 19, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 No price data
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $33.32 Now $32.24 −3.24% settles Dec 11
  3. Oct 19, 202628d ago 8-K Bullish 6/10 Entry $26.16 Now $32.24 +23.24% settles Nov 17
  4. Oct 19, 202628d ago Press Release Bullish 7/10 Entry $24.60 to $32.88 Now $32.24 +31.06% ▲ +33.66% +37.12% vs SPY
  5. Oct 1, 20266w ago 8-K Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
  6. Oct 1, 20266w ago Press Release Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
  7. May 14, 202626w ago 8-K Neutral 4/10 Entry $23.21 to $18.44 Now $32.24 +38.91% ▼ −20.55% −22.67% vs SPY
  8. Mar 26, 202633w ago Press Release Bullish 8/10 Entry $22.61 to $23.65 Now $32.24 +42.59% ▲ +4.60% −8.14% vs SPY
  9. Mar 9, 202636w ago Press Release Bullish 8/10 Viewing Entry $27.12 to $21.07 Now $32.24 +18.88% ▼ −22.31% −19.50% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens Wed (11h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 9, 2026